IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

IDEXX Laboratories, Inc. (NASDAQ:IDXX) has been assigned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $783.3333.

IDXX has been the subject of several analyst reports. Wall Street Zen raised shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 7th. BTIG Research cut their price target on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. JPMorgan Chase & Co. lifted their price objective on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Morgan Stanley boosted their price objective on shares of IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, UBS Group cut their target price on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research note on Tuesday, February 3rd.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $635.66 on Friday. IDEXX Laboratories has a 52-week low of $356.14 and a 52-week high of $769.98. The company has a market cap of $50.76 billion, a P/E ratio of 48.64, a P/E/G ratio of 3.87 and a beta of 1.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The stock’s 50-day simple moving average is $677.74 and its 200 day simple moving average is $669.01.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing the consensus estimate of $2.93 by ($0.01). The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period last year, the company posted $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, sell-side analysts forecast that IDEXX Laboratories will post 11.93 EPS for the current fiscal year.

More IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Analyst support remains a tailwind — multiple firms continue to rate IDXX favorably (Jefferies, BTIG, Barclays among others) and the consensus remains a “Moderate Buy” with a material above‑current price target consensus. That analyst backdrop can support buying interest. Read More.
• Neutral Sentiment: Company fundamentals: IDXX reported a slight EPS miss (by $0.01) for the most recent quarter but beat on revenue (+14% y/y) and provided FY‑2026 EPS guidance of $14.29–$14.80 — guidance is above many near‑term expectations, which is generally constructive for the stock. Read More.
• Neutral Sentiment: Re‑rating narrative: recent commentary (Conestoga/InsiderMonkey, Yahoo syndicated pieces) argues IDXX shares are re‑rating toward historical averages — this is discussion‑driven and could help multiple investors re‑allocate into the name if the argument gains traction. Read More.
• Neutral Sentiment: Comparisons in the sector: valuation/sector pieces (e.g., Zacks comparing SONVY vs IDXX) may influence relative‑value flows but don’t present new company‑specific catalysts. Read More.
• Neutral Sentiment: Short‑interest data posted for February appears to show zero shares / zero days‑to‑cover (likely a reporting anomaly). That suggests no clear short‑squeeze pressure at present but verify with exchange short‑interest releases.
• Negative Sentiment: Insider selling: multiple execs disclosed sizable sales on Feb 17 — Director Sophie Vandebroek sold 1,464 shares (~$628.62 avg) and EVP Michael Erickson sold 5,371 shares (~$627.38 avg). Large insider sales can be read as signal of personal liquidity/positioning and may weigh on near‑term sentiment. Read More. Read More.

Insider Activity

In other news, Director Sophie V. Vandebroek sold 1,464 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the completion of the sale, the director directly owned 648 shares of the company’s stock, valued at $407,345.76. This trade represents a 69.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total value of $7,337,038.40. Following the transaction, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. The trade was a 53.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 18,180 shares of company stock valued at $11,626,996 over the last three months. Insiders own 0.98% of the company’s stock.

Hedge Funds Weigh In On IDEXX Laboratories

Several large investors have recently modified their holdings of the stock. Compound Planning Inc. boosted its holdings in shares of IDEXX Laboratories by 51.9% during the 4th quarter. Compound Planning Inc. now owns 1,802 shares of the company’s stock worth $1,219,000 after buying an additional 616 shares during the period. Invesco Ltd. lifted its position in IDEXX Laboratories by 13.8% during the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock worth $1,016,296,000 after acquiring an additional 181,955 shares during the last quarter. Axxcess Wealth Management LLC lifted its position in IDEXX Laboratories by 37.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 1,707 shares of the company’s stock worth $1,155,000 after acquiring an additional 465 shares during the last quarter. Birchwood Financial Partners Inc. bought a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $82,000. Finally, Corient Private Wealth LLC grew its position in shares of IDEXX Laboratories by 58.9% in the fourth quarter. Corient Private Wealth LLC now owns 184,587 shares of the company’s stock valued at $124,879,000 after purchasing an additional 68,410 shares during the last quarter. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.